Introduction to Research-Grade Human CiPS Cell Lines
Pluripotent stem cells have the unique ability to proliferate indefinitely and differentiate into nearly all types of functional cells in the body. The team led by Professor Hongkui Deng at Peking University pioneered a chemical reprogramming method that uses only small chemical molecules to reverse cell fate, reprogramming human cells into pluripotent stem cells, known as human chemically induced pluripotent stem cells (hCiPSCs).
BeiCell Therapeutics has utilized this chemical reprogramming technology to establish a series of rigorously screened and quality-controlled hCiPS cell lines derived from healthy individuals through single-clone sources. These cell lines exhibit typical molecular characteristics and differentiation potential of pluripotent stem cells, can be stably passaged over the long term, and are valuable resources for stem cell research, tissue repair, disease mechanism studies, and drug development. As a third-generation somatic cell reprogramming technology, chemical reprogramming avoids the safety concerns associated with traditional reprogramming methods. The cell lines established using this technology can serve as seed cells for research and development related to cell therapy products, providing a safer option for clinical applications.
Advantages of Research-Grade Human CiPS Cell Lines
· Induced through chemical reprogramming technology
· Non-integrative method, no residual exogenous factors
· Derived from healthy individuals, single-clone sources
· Low passage number, capable of long-term expansion
Research-Grade Human CiPS Cell Line Inventory:
ID | Name | Cells per vial | Passage Number |
hCiPSC-00409 | Human CiPS Cell Line (Female, 25 years) | >1 x 10⁶ | <P10 |
hCiPSC-00605 | Human CiPS Cell Line (Female, 23 years) | >1 x 10⁶ | <P10 |
| hCiPSC-00711 | Human CiPS Cell Line (Female, 35 years) | >1 x 10⁶ | <P10 |
Contact Us
Research-grade human CiPS cell lines require the signing of a Material Transfer Agreement (MTA) for access. For more information, please contact us at:
Ms. Wang, Tel: +86 13716368939, Email: xiaoqing.wang@beicelltherapeutics.com
※ For commercial use inquiries or to establish specific research hCiPS cell lines, please contact us at BD@beicelltherapeutics.com.
Contact us
Business email: BD@beicelltherapeutics.com
Recruitment email: recruit@beicelltherapeutics.com
Office address: Unit 201, Zhongguancun Science City Star Valley, Building B, No.4 Yongjia North Road, Haidian District, Beijing
Laboratory address: Ground Floor, Zhongguancun Science City Star Valley, Building B, No.4 Yongjia North Road, Haidian District, Beijing
